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Long-term Prognostic Significance of Treadmill
Ischemia in "Low-risk" Patients with Coronary
Artery Disease
David Mulcahy, Asi! Rehman, Syed S. Husain, Neil P. Andrews, Gloria Zalos,
William H. Schenke. Arshed A. Ouyyumi. NHLBI, Bethesda, MD
was performed at 4 weeks, LV end-diastolic (EDVI) volume (mllm2), Lown-
grade and OT-duration, corrected for heart rate (OTc, ms) were measured at
4 days, 4 weeks, 0.5,1.5, and 3 years by gated SPECT, Holter and 12-channel
ECG, respectively. During an average follow-up of 59.7 months, 16 patients
died (mortality 12.2%, median survival time of 30 months). Death was pro-
ceeded by progressive LV dilation (left figure) and occurred suddenly in 14
of 16 patients (88%). Extend and severity of ventricular arrhythmias, as indi-
cated by a rise of Lawn-grade from 2.8 ± 0.5 to 3.6 ± 0.5, 5.0 ± 0.4, 5.4 ±
0.3 and 5.8 ± 0.2 at 4 days, 4 weeks, 6 months, 1.5 and 3 years, respectively
(p < 0.00001), increased before death. This was associated with a rise of
OTc from 457 ± 6 at 4 days to 480 ± 9 before death (p = 0,01). In contrast,
EDVI (left Figure) and Lown-grade did not rise and OTc even decreased (457
± 8, 456 ± 8, 424 ± 4, 414 ± 5, 399 ± 4) in survivors (p < 0.05). Extend of
LV dilatation correlated with severity of ventricular arrhythmias (right Figure).
Non-survivors did not differ in drug therapy, electrolytes or initial coronary
status and exercise tests were negative. These findings indicate that pro-
gressive LV dilatation (remodeling I may provide a proarrhythmic substrate
for sudden death after Mi, which deserves more detailed analysis.
Patients with stable single or 2-vessel coronary artery disease (CAD) and nor-
mal, or mildly depressed left ventricular function have a good prognosis. We
have investigated the long-term prognostic significance of a positive exercise
test (ExTestl in this population to establish whether it is useful in identifying
a "high-risk" subgroup within a recognised "low-risk" population. Between
1987-94,162 patients with documented single (n = 89) or double (n = 73)
vessel CAD (exclUding left main and proximal left anterior descending CAD),
left ventricular ejection fraction >35% (mean 51 %, range 36-72%) on ra-
dionuclide ventriculography, and an interpretable ExTest were assigned to
receive medical therapy. There were 123 males and 39 females (mean age
60 yrs). A positive ExTest for ischemia was present in 104 (64%) pts. Pts
were followed for a mean period of 49 months (range 6-82 months), during
which time 34 (21 %) had cardiac events (cardiac death n = 3, myocardial
infarction (AMI) n = 14, unstable angina n = 6, elective revascularisation n =
11). Similar proportion of pts with a positive ExTest and a negative ExTest suf-
fered cardiac events (all events, including revascularization) during follow-up
(21 % and 20.7% respectively). Kaplan Meier survival analysis demonstrated
no difference between the groups. Survival analysis also failed to demon-
strate any difference in the incidence of acute cardiac events (cardiac death
and AMI) between positive and negative ExTest groups; of 15 events, 6 (40%)
occurred in those with a positive Extest. Pts with 2-vessel disease suffered
significantly more events than those with I-vessel disease (29% vs 14.6%, P
< 0.05), but there was no difference in acute events (cardiac death and AMI)
between the two subsets. Even in pts with 2-vessel disease, there was no
difference in survival in those with and without a positive ExTest. The data
indicate that although detection of ischemia by exercise testing is useful as
an initial diagnostic tool, once the coronary anatomy and left ventricular func-
tion are known, the presence of ischemia on treadmill exercise is of limited
prognostic value in "low-risk" pts with stable CAD. These findings are consis-
tent with reports demonstrating that acute cardiac events often result from
plaque rupture in non-significantly stenosed vessels.
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Inadequate Pre-Hospital Medical Therapy in
Patients Undergoing Percutaneous Coronary
Revascularization: Results from the CAVEAT Trial
Mark J. Eisenberg, Louise Pilote, Gordon Keeler, Robert M. Califf, Eric J. Topol,
CAVEAT investigators. Cleveland Clinic Foundation, Cleveland, OH
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Suspected Ischemic Chest Pain: Accuracy and
Cost Efficiency of Emergency Department-based
Evaluation
Ester LeVin, Maureen Lowery, Richard B. Furlong, Robert J. Myerburg. University of
Miami; MiamI; FL
Hospital admissions to exclude myocardial ischemia as one possible cause
of unexplained chest pain (CP) are costly and have a low positive diagnostic
yield. This prospective study was performed to determine whether a compre-
hensive emergency department (ED I-based cardiology service provides ac-
curate diagnoses with a significant cost savings. A special cardiology service
providing consultations, exercise testing and echocardiography was used to
evaluate 97 consecutive emergency department patients (pts) (44 male, 53
female) who presented with CP The pts had one or more risk factors for coro-
nary artery disease, a suspicious but atypical CP pattern, and no ECG/enzyme
evidence of acute myocardial injury. To qualify, each pt had to be considered
an appropriate candidate for hospital admission to evaluate CP by the ED
physician. Based on negative exercise testing results performed upon clin-
ical evaluation in the ED, all pts were discharged to continued non-cardiac
ambulatory work-up. Mean cost of the evaluation was $1683 ± $871. A con-
trol group of 36 pts with similar symptoms underwent identical diagnostic
procedures on an in-patient basis. In all cases, myocardial ischemia origin of
the CP was excluded and the pts were discharged to various out-patient ser-
vices. The mean cost of their hospital stay was $6358 ± $1884. We conclude
that comprehensive cardiology service within an emergency department is
a reliable alternative to hospitalization and results in a 74% cost-reduction
for evaluation of a pt with atypical chest pain.
evening. After correcting ischemic time for each patient's simultaneously
measured activity level, a significant circadian fluctuation of ischemic time
was still observed (p < 0.001) with an early morning peak at 6 a.m.
Conclusion: There is an underlying endogenous circadian rhythm of is-
chemic vulnerability, which is independent of exogenous factors. Exogenous
factors are most potent as triggers of ischemia at the time of morning peak
of the endogenous variation in vulnerability for ischemia.
Background: Patients with known coronary artery disease rnay be receiv-
ing inadequate medical therapy prior to referral for percutaneous coronary
revascularization. Methods: To examine the medical treatment of patients re-
ferred for percutaneous coronary revascularization, we analyzed pre-hospital
treatment data and concomitant medical conditions from the CAVEAT I trial.
Results: Of the 1,012 patients referred for revascularization 68.3% had unsta-
ble angina, 17.6% had stable angina, 9.8% had chest pain after myocardial
infarction, and 4.3% were asymptomatic with a positive functional study.
Prior to PTCA or directional atherectomy (DCA), patients had low rates of
treatment with aspirin, nitrates, calcium channel blockers, beta-blockers, and
anti-lipid agents (Table). Pre-hospital medications were associated with the
following conditions: aspirin-none, nitrates-none, calcium channel blockers-
hypertension (p = 0.004) and absence of unstable angina (p = 0.046), beta
blockers-hypertension (p = 0.01), and anti-lipid agents-hyperlipidemia Ip =
0.0001) and number of diseased vessels (p = 0035). Conclusions: These
data strongly indicate that patients referred for percutaneous coronary revas-
cularization have inadequate pre-hospital medical treatment.
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Georg Ertl. University of Wurzburg, Germany: 1Regensburg. Germany
Although left ventricular (LV) dilation after myocardial infarction (Mi) carries
an adverse prognosis, it is unclear whether individual patients indeed die
with progressive remodeling, and how dilation is related to death.
We assessed 131 consecutive asymptomatic patients during 5 years after
uncomplicated first myocardial infarction (Mi). In each, coronary angiography
Nina Rehnqvist. Paul Hjemdahl 1, Ewa Billing, Inge Bjorkander, Sven V Eriksson,
Lennart Forslund, Claes Held, Per Nasman, N. Hakan Wallen 1. Karolinska Instituter.
Department of Internal Medicine, Danderyd Hospital, Danderyd, Sweden; 1 Department
of Clinical Pharmacology- Karolinska Hospital- Stockholm, Sweden
The effect of treatment with metoprolol or verapamil was investigated in 809
patients with stable angina pectoris. End points for the study were: death,
!990-51 I Mechanisms and Predictors of Late Death in
Asymptomatic Patients After Myocardial
Infarction. A Prospective Study on Remodeling
1990-53 1 Effects on Cardiovascular End Points and
Psychological Variables of Metoprolol and
Verapamil in Patients with Stable Angina Pectoris
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Ideal antiarrhythmic therapy may not impact on AD and tDtal death as sus-
pected; in the ESVEM trial, the 1 and 4 year actuarial mortality from OH AD
was 8% and 18%. These values may indicate more precisely those patients
who benefit from prefect antiarrhythmic therapy. With 8% 1 year OH-AD,
92% cou Id be treated unnecessarily.
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Decreasing Risk of Symptomatic Sustained
Ventricular Tachycardia in Myocardial Infarction
Patients
Dietrich Andresen, Gerhard Steinbeck 1, Rudiger Dissmann, Richard Stern,
Elke Hoffmann 1, Thomas Bruggemann, Gerlinde Langenscheidt,
Dominique Rumor, Klinikum Benjamin Franklin. Free University of Berlin, Germany:
1 University ofMunich, Germany
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nonfatal cardiovascular events and three psychological variables reflecting
aspects of quality of life. Nonfatal cardiovascular events included acute my-
ocardial infarction, incapacitating or unstable angina, cerebrovascular and
peripheral vascular events. The psychological variables were aggregate mea-
sures of psychosomatic symptoms and sleep disturbances and an evaluation
of life satisfaction on a visual analogue scale. The mean age of the patients
was 59 ± 7 years and 30% were women. The patients were followed for a
total of 2887 patient years, with a median follow-up time of 3.6 years. To-
tal cardiovascular mortality in the metoprolol versus verapamit group were
5.4% versus 6.2% and 4.7% versus 4.7% respectively. Nonfatal cardiovas-
cular events occurred in 26.4 and 24.1 %, respectively. Psychosomatic symp-
toms and sleep disturbances were significantly improved in both treatment
groups. The magnitude of change was small and not significantly different.
Life satisfaction did not change on either drug. Withdrawals due to side ef-
fects occurred in 11.1 and 14.6%, respectively.
Conclusion: This large scale long term study shows that both drugs were
well tolerated and had the same effect on mortality, cardiovascular end
points and measures of quality of life.
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Electrophysiologic Findings in Patients with
Obstructive Sleep Apnea Associated Ventricular
Asystole
Wolfram Grimm, Jurgen Hoffmann, Ulrich Kohler, Volker Menz, Jorg H. Peter,
Bernhard Maisch. Philipps-University Marburg. Germany
Our knowledge Df natural history in survivors following myocardial infarction
(Mil is mainly based on data collected before the fibrinolytic era. In a prospec-
tive risk stratification study, 823 MI survivDrs underwent 24-h Holter moni-
toring (HMl 12-16 days after the acute event. Ventricular extrasystoles (VES)
were present in 77% of the pts, ::: 20 VES/h in 10%. ventricular pairs (VP)
in 27%, ventricular salvoes (VS) in 12% and nonsustained ventricular tachy-
cardias (>5 consecutive VES}(nsVT) in 9%. During the 12-months follow-up
(only one patient was lost) there were 66 (8%) deaths, 26 sudden or instanta-
neous (SD)(39%). 23 non-sudden, 6 non-cardiac and 11 of unknown causes.
SO-rates were 3% in thDse with monomorphic YES, 9% with :;:20 VES/h or
Vp, 10% with VS and 13% with nsVT (p = 0.01). Only one pt developed a
symptomatic sustained ventricular tachycardia 2 months after discharge and
only 5 pts had syncopes of unknown origin.
Conclusion: In the fibrinolytic era, arrhythmias are still as prevalent as at
the time before thrombolysis. The sudden death rate is also similar. However,
symptomatic sustained ventricular tachycardia has become an extremely
rare event.
Fourteen patients (47 ± 11 years) with ventricular asystDle of 5.6 ± 2.7
sec (range: 3.1-13.6 sec) due to complete atrioventricular (AV) block (n =
8). sinoatrial (SA) block or sinus node (SN) arrest (n = 5) or both (n = 1)
occurring exclusively during sleep apnea episodes as documented by car-
diorespiratory polysomnography underwent conventional electrophysiologic
study: evaluation of sinus node function included rate corrected SN recovery
time (CSNRT), sinoatrial conduction time (SACT, Narula method). and sinus
rate (SR) response to atropine (0.02 mglkg). CSNRT of <550 ms, SACT of
<125 ms, and SR increase after atropin to >90 bpm were considered to be
normal. Assessment of AV-conduction included AH- and HV-intervals. AV-
Wenckebach periods, and AV nodal effective refractory periods (ERPs) be-
fore and after atropine. None of the 14 pts received digitalis, beta-blockers
or verapamil during polysomnography or EP study. 6 pts (42%) had hyperten-
sive heart disease, 1 pt (8%) had cDronary disease, and 7 pts (50%) showed
no evidence of structural heart disease.
Results: SN function was normal in 12 of 14 pts (86%). Two pts had slightly
prolonged SACTs (160 and 165 ms respectively). CSNRT and SR response to
atropine was normal in all pts. AV nodal function was normal in 8 of 14 pts
(57%) and abnormal in 4 pts (43%): 2 pts had prolonged AH-intervals Df 135
and 143 ms, and 2 pts had AV-Wenckebach points at 520 and 730 ms and
AV nodal ERPs of 500 and 700 ms respectively. AV-nodal function normalized
after administration of atropine in all 4 pts. His-Purkinje system function was
normal in 8 pts (57%), and 6 pts (43%) had slightly prDlonged HV-Intervals
(range: 59-63 ms). Intra- or infra His block was not observed in any pt.
In conclusiDn. normal or only slightly abnormal electrophysiologic findings
in most patients with sleep apnea associated ventricular asystole support the
hypDthesis that ventricular asystole is due to a neurally mediated cardioin-
hibitory reflex. However, it remains unsolved, why sleep apnea associated
prolonged ventricular asystole does occur in some pts and does not occur
in other pts despite severe obstructive sleep apnea.
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Out-of-Hospital versus In-Hospital Death in the
ESVEM Trial
Potential Impact of Serial Drug Testing on the
Clinical Outcome of Survivors of Cardiac Arrest,
as Assessed in the Propafenone Arm of CASH
Trial
Jurgen Siebels. Riccardo Cappato. Rudolf Ruppel, Michael Schneider.
Michael Schluter. Thomas Meinertz. Karl-Heinz Kuck. University Hospital Eppendorf
and SI Georg Hospital, Hamburg
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The study design olthe Cardiac Arrest Study Hamburg (CAS H) trial allows ret-
rospective assessment of serial drug testing (SOT) predictive value. Regard-
less of pts assignment to Dne of the 3 drug arms (propafenone (P), metopro-
101 and amiodarone) all pts undergo programmed electrical stimulation (PES)
before and after oral drug administration; the assigned drug is then adminis-
tered regardless of the response to SOT. DisciDsure of data on P and ICD in
survivors of cardiac arrest after premature termination of the former arm al-
lowed retrospective assessment of the predictive value of SOT. In the P arm,
age was 57 ± 13 yrs; 46 (79%) out Df 58 pts had ischemic heart disease. Dur-
ing baseline PES. a sustained ventricular arrhythmia (sVA) could be induced
in 25 (63%) pts assigned to P After oral P(300-900 mg/day). 13 (52%) among
inducible, but 22 (67%) among nDninducible pts at baseline presented a sVA
in response to PES. During a median follDw-up of 11 months, sVA or sudden
death occurred in 2/13 (15%) nonresponders, 2/5140%) respDnders. in 2/7
(29%) pts who became inducible after P and in 3/22 (14%) whD were not in-
ducible during baseline and after P The second PES could not be performed
in 11 (19%) pts due to the occurrence of spontaneous VA arrhythmias after
P administration; sVA during follow-up were dDcumented in 5 (45%) such
pts. The positive and the negative predictive values of SOT with P were 60%
and 15%, respectively.
Conclusion. Data from this study suggest that, in survivors of cardiac ar-
rest, SOT with P carries a poor predictive value to guide drug therapy. This
observatiDn prompts further investigatiDn to assess the utility of SOT as a
strategy in pts at risk of sudden death.
Brian Olshansky, Vernon Hartz. Elizabeth Hahn, Jay Mason, ESVEM Investigators.
Loyola University Medical Centere, Maywood, IL
Perfect antiarrhythmic therapy may not impact on total arrhythmic death (AD)
(defined as death associated with ventricular tachycardia, ventricular fibrilla-
tion or asystole) or all cause mortality if AD is not preventable. Death asso-
ciated with an arrhythmia may occur in-hospital (IH) as an inevitable conse-
quence of the disease process, be considered AD and not be preventable.
Out-of-hospital AD, however, may be preventable by perfect antiarrhythmic
therapy. We evaluated IH-AD, OH-AD, non-arrhythmic cardiac death ICARI,
non-cardiac death (NCO) and total deaths in the ESVEM trial in all 486 pa-
tients randomized. Deaths were OH-AD if arrhythmic death occurred OH or
if out of hospital arrhythmias preceded admission and directly caused death.
OH AD accounted for 41 % of all deaths. Baseline characteristics were CDm-
parable for OH-AD and IH-AD groups (e.g., ejection fraction, disease etiology.
sex, age, beta blocker use, prior antiarrhythmic drug failure). Eighty-six per-
cent of OH deaths were AD while 22% of IH deaths were AD (P < 0.001).
Twenty of 87 arrhythmic deaths occurred in the hospital.
